Literature DB >> 17200181

B-cell epitope spreading is a critical step for the switch from C-protein-induced myocarditis to dilated cardiomyopathy.

Yoh Matsumoto1, Il-Kwon Park, Kuniko Kohyama.   

Abstract

Repeated inflammation in the heart is one of the initiation factors of dilated cardiomyopathy (DCM). In a previous study, we established a new animal model for DCM by immunization of rats with recombinant cardiac C-protein fragment 2 (CC2). The present study examined factors involved in the development of DCM. Analysis using overlapping peptides revealed that the major carditogenic epitope resides only in the residue 615-647 [CC2 peptide 12 (CC2P12)]. However, immunization with CC2P12 induced moderate inflammation without subsequent DCM. CDR3 spectratyping analysis of the T-cell repertoire demonstrated that Vbeta4-positive T cells were preferentially expanded in both CC2- and CC2P12-immunized rats. Although there was no significant difference in the T-cell characteristics, examinations of the B-cell epitope revealed that marked epitope spreading occurred in CC2-immunized but not CC2P12-immunized rats from 4 weeks after immunization. Consistent with this finding, immunization with CC2P12 and simultaneous transfer of anti-peptide antisera induced significantly more severe inflammation and fibrosis than CC2P12 immunization alone. However, the transfer of the antisera without CC2P12 immunization did not induce any pathology. These findings suggest that T-cell activation and B-cell epitope spreading in the CC2 molecule is a key step for the switch from myocarditis to the development of DCM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200181      PMCID: PMC1762711          DOI: 10.2353/ajpath.2007.060544

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.

Authors:  R Wojnicz; E Nowalany-Kozielska; C Wojciechowska; G Glanowska; P Wilczewski; T Niklewski; M Zembala; L Polonski; M M Rozek; J Wodniecki
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

2.  Advances in the understanding of myocarditis.

Authors:  P P Liu; J W Mason
Journal:  Circulation       Date:  2001-08-28       Impact factor: 29.690

3.  Successful TCR-based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR.

Authors:  Y Matsumoto; Y Jee; M Sugisaki
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

4.  Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy.

Authors:  J Müller; G Wallukat; M Dandel; H Bieda; K Brandes; S Spiegelsberger; E Nissen; R Kunze; R Hetzer
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

5.  Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes.

Authors:  H E Naserke; A G Ziegler; V Lampasona; E Bonifacio
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

6.  CDR3 size spectratyping and sequencing of spectratype-derived TCR of spinal cord T cells in autoimmune encephalomyelitis.

Authors:  G Kim; N Tanuma; T Kojima; K Kohyama; Y Suzuki; Y Kawazoe; Y Matsumoto
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

7.  Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.

Authors:  C L Vanderlugt; K L Neville; K M Nikcevich; T N Eagar; J A Bluestone; S D Miller
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

8.  Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients.

Authors:  R S Warraich; M J Dunn; M H Yacoub
Journal:  Biochem Biophys Res Commun       Date:  1999-06-07       Impact factor: 3.575

9.  Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution.

Authors:  A Staudt; F Schäper; V Stangl; A Plagemann; M Böhm; K Merkel; G Wallukat; K D Wernecke; K Stangl; G Baumann; S B Felix
Journal:  Circulation       Date:  2001-06-05       Impact factor: 29.690

10.  Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody.

Authors:  Lisa Larsson; Reza Mobini; Pål Aukrust; Lars Gullestad; Gert Wallukat; Finn Waagstein; Michael Fu
Journal:  Autoimmunity       Date:  2004 Sep-Nov       Impact factor: 2.815

View more
  7 in total

Review 1.  Immune cell diversity contributes to the pathogenesis of myocarditis.

Authors:  Xiumeng Hua; Jiangping Song
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 2.  The Role of B Cells in Cardiomyopathy and Heart Failure.

Authors:  Kevin Bermea; Aashik Bhalodia; Angelo Huff; Sylvie Rousseau; Luigi Adamo
Journal:  Curr Cardiol Rep       Date:  2022-06-11       Impact factor: 3.955

Review 3.  Unresolved issues in theories of autoimmune disease using myocarditis as a framework.

Authors:  Robert Root-Bernstein; DeLisa Fairweather
Journal:  J Theor Biol       Date:  2014-12-04       Impact factor: 2.691

4.  Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome.

Authors:  Thomas L Lynch; Diederik W D Kuster; Beverly Gonzalez; Neelam Balasubramanian; Nandini Nair; Sharlene Day; Jenna E Calvino; Yanli Tan; Christoph Liebetrau; Christian Troidl; Christian W Hamm; Ahmet Güçlü; Barbara McDonough; Ali J Marian; Jolanda van der Velden; Christine E Seidman; Gordon S Huggins; Sakthivel Sadayappan
Journal:  JACC Basic Transl Sci       Date:  2016-12-19

Review 5.  Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

6.  Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series.

Authors:  Carsten Tschöpe; Sophie Van Linthout; Frank Spillmann; Maximilian G Posch; Petra Reinke; Hans-Dieter Volk; Ahmed Elsanhoury; Uwe Kühl
Journal:  Eur Heart J Case Rep       Date:  2019-09-01

Review 7.  Surviving the infarct: A profile of cardiac myosin binding protein-C pathogenicity, diagnostic utility, and proteomics in the ischemic myocardium.

Authors:  Thomas L Lynch; Sakthivel Sadayappan
Journal:  Proteomics Clin Appl       Date:  2014-07-14       Impact factor: 3.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.